Skye Bioscience (SKYE) Assets Average (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Assets Average of $23.9 million for Q1 2026, down 65.3% year-over-year from $68.8 million in Q1 2025, and down 31.46% quarter-over-quarter from $34.8 million in Q4 2025.
Skye Bioscience (SKYE) Assets Average (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Assets Average for 14 consecutive years, with $23.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 65.3% year-over-year to $23.9 million; the TTM figure through Mar 2026 stood at $23.9 million (down 65.3% YoY), while the FY2025 annual figure was $50.5 million, up 19.33% from the prior year.
- Assets Average retreated to $23.9 million in Q1 2026 per SKYE's latest filing, from $34.8 million in the prior quarter.
- Across five years, Assets Average topped out at $91.0 million in Q2 2024 and bottomed at $3.4 million in Q2 2023.
- Historically, Assets Average has averaged $35.1 million across 5 years, with a median of $23.9 million in 2026.
- Annual changes were most pronounced in 2024 — Assets Average surged 2568.92% — and 2026, when it plunged 65.3%.
- Skye Bioscience's Assets Average stood at $6.0 million in 2022, then surged by 129.92% to $13.8 million in 2023, then soared by 460.18% to $77.1 million in 2024, then plunged by 54.87% to $34.8 million in 2025, then sank by 31.46% to $23.9 million in 2026.
- Business Quant data shows SKYE's Assets Average at $23.9 million in Q1 2026, $34.8 million in Q4 2025, and $46.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.87 Mn |
| Dec 31, 2025 | 34.82 Mn |
| Sep 30, 2025 | 46.74 Mn |
| Jun 30, 2025 | 58.48 Mn |
| Mar 31, 2025 | 68.78 Mn |
| Dec 31, 2024 | 77.15 Mn |
| Sep 30, 2024 | 84.40 Mn |
| Jun 30, 2024 | 91.05 Mn |
| Mar 31, 2024 | 53.39 Mn |
| Dec 31, 2023 | 13.77 Mn |
| Sep 30, 2023 | 8.92 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Mar 31, 2023 | 6.85 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 6.09 Mn |
| Mar 31, 2022 | 8.53 Mn |
| Dec 31, 2021 | 10.77 Mn |
| Sep 30, 2021 | 8.59 Mn |
| Jun 30, 2021 | 5.44 Mn |